Clinical Trial COGACCL0922


SCUSF0901 - ACCL0922: A Phase II Placebo-Controlled Trial of Modafinil to Improve Neurocognitive Deficits in Children Treated for a Primary Brain Tumor

Principal Investigator(s)

Adam Esbenshade


  • Protocol No. COGACCL0922
  • Open Date: 02/20/2013
  • Staging: Phase II
  • Age Group: Children
  • Scope: International
  • Objective: The primary objective of this study is to determine whether a 6-week drug trial of modafinil, compared to placebo, is associated with improvement in neurocognitive function as defined by parent report of inattention or working memory deficits or by direct assessment of attention, working memory or processing speed in children with cognitive impairment after treatment for a primary brain tumor.
  • Disease Sites: Pediatric Solid Tumors
  • Therapies: Molecular Targeted Agents / Immunotherapy / Biologics
  • Drugs: Modafinil
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01381718
  • Secondary Protocol No: ACCL0922



Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.